Guillaume joined Rheos as Senior Director, Head of Chemistry in January 2018, and is currently serving as interim Head of Drug Discovery. Guillaume brings over 12 years of experience in both early and late-stage drug discovery. He started his career at Merck Frosst in Montreal, where he was part of the team that discovered Doravirine (MK-1439), a marketed NNRTI for the treatment of HIV. Guillaume then transitioned to Novartis, where he supported drug discovery programs across several target classes and led a team to the discovery of HSY244, currently in clinical development for the treatment of atrial fibrillation. More recently, Guillaume led a multi-functional team across multiple GSK sites worldwide to a Th17-modulating development candidate for autoimmune diseases.
Guillaume obtained his Ph.D. in Organic Chemistry from the University of Montreal and his B.Sc./M.Sc. in Chemistry from the University of Sherbrooke.